Medicare's New $50 Weight-Loss Drug Program: What You Need to Know

Medicare launched a temporary weight-loss drug program on July 1, 2026, offering three GLP-1 medications—Wegovy, Zepbound (KwikPen form), and Foundayo (tablet)—to eligible beneficiaries at a flat $50 monthly copay. The Centers for Medicare & Medicaid Services (CMS) announced the model in December 2025 as a separate track from the standard prescription drug benefit.

To qualify, you must be enrolled in a Part D plan (Medicare's prescription drug coverage) and using the medication specifically for weight loss, not diabetes. This distinction matters: if you take a GLP-1 for type 2 diabetes instead, it runs through the regular Part D process. CMS extended the program through December 31, 2027, giving the agency 18 months to study how many people use it and whether it works.

Why the $50 Copay Is a Big Deal

These drugs carry sticker prices above $1,000 a month. Under normal Medicare Part D rules, even with the $2,000 annual cap on out-of-pocket costs that took effect after the Inflation Reduction Act, beneficiaries would likely pay far more per dose—particularly for specialty drugs. The Bridge sidesteps that by offering a fixed, predictable cost. You know exactly what you'll pay each month, which can help people decide whether to start and stick with treatment.

The program works outside the standard Part D benefit, which changes how insurance plans handle the claims and costs. Plans are not required to participate—it's voluntary—so coverage will vary depending on which Part D plan you're in. This creates a patchwork: some seniors will have access at the $50 price, others won't, depending on their plan choice.

The Bigger Picture: Medicaid and Overall Drug Spending

The contrast with Medicaid is instructive. An HHS Office of Inspector General report from December 2024 found that Medicaid spent more than $9 billion on ten selected diabetes drugs and two weight-loss drugs in 2023—a 540% jump from 2019. Most state Medicaid programs cover GLP-1s for diabetes but not for weight loss, yet spending has already surged. If states begin covering these drugs for obesity, that bill will grow substantially higher.

Before the Inflation Reduction Act, Medicare was barred from covering weight-loss drugs outright. The law changed that prohibition, and the Bridge is CMS's first move to operationalize it. The $50 copay is purposefully set to encourage people to try these medications while keeping the cost visible—it signals that CMS is treating this as both a coverage expansion and an experiment to gather real-world data.

What Happens Next: The 18-Month Window

The program's temporary nature matters more than it might appear. CMS can adjust the model, extend it, or end it when the window closes at the end of 2027. If too many people sign up and spending explodes, or if the health outcomes disappooint, the agency retains the option to reshape the benefit or close it without having permanently locked it into the standard Part D framework.

For the three drugmakers involved—Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have long track records with these therapies, while Foundayo (a tablet form) offers a third option—this coverage milestone matters strategically. Getting into Medicare, even temporarily, establishes a reimbursement foothold and opens access to 67 million beneficiaries for the obesity indication. Both Novo Nordisk and Eli Lilly have been ramping up manufacturing in anticipation of exactly this kind of expansion.

Insurance plan sponsors face immediate decisions about which of the three drugs to feature and how to ensure pharmacies can fill prescriptions reliably. Pharmacy benefit managers—the companies that negotiate drug prices on behalf of insurers—are working within a CMS structure where the list price, the net price after rebates, and the $50 patient cost are all active variables. This is different from standard Part D negotiation and requires separate tracking of claims and costs.

The broad context here is one of managed expansion under close watch. CMS is not betting the farm on permanent coverage yet. It's piloting, measuring, and preserving the option to pivot or scale back based on what the data shows over the next 18 months.